The US Food and Drug Administration’s priority review voucher programs appear poised for legislative attention this year, with the rare pediatric disease program due to sunset in September and the agency itself calling on Congress to clarify what types of biologic products are eligible for vouchers.
In addition, a recent Government Accountability Office report suggests potential legislative and regulatory changes across the voucher programs, which remain...






